2.1. COVE Trial and Study Endpoint
COVID-19 disease
SARS-COV-2 INFECTION
The COVE trial (NCT04470427), conducted in the United States, enrolled 30,420 adults age 18 and over at appreciable risk of SARS-CoV-2 infection and/or high risk of severe COVID-19 disease and randomly assigned them in a 1:1 ratio to receive either vaccine or placebo [